Deep Health AI has corrected an audit procedural omission. The company reported a failed acquisition of Oasis Ceramics and a diversion of ₹37.47 crore from its Rights Issue funds, with shareholders ratifying the deviation. Auditors issued an unmodified opinion.
Deep Health AI Ltd. Reports Audit Correction and Strategic Setbacks
₹37.47 crore Rights Issue funds diverted; ₹3.21 crore bank guarantee invoked.
Reader Takeaway: Audit correction, but significant capital allocation concerns and a failed acquisition leading to financial loss.
What just happened
Deep Health AI India Ltd. has filed a revised Auditor's Report for FY 2025-26 to rectify a procedural omission concerning the list of entities in its consolidated financial statements. Management has confirmed these changes do not alter the reported financial results. The auditor maintained an unmodified opinion for both standalone and consolidated statements.
Why this matters
While the audit correction is procedural, the filing highlights significant operational and strategic challenges. The company failed to complete the acquisition of Oasis Ceramics Pvt. Ltd., leading to a ₹3.21 crore bank guarantee being invoked. Furthermore, ₹37.47 crore, out of ₹39.97 crore raised via a Rights Issue, was utilized for purposes other than originally stated, a deviation later ratified by shareholders.
The backstory
The company had planned to acquire Oasis Ceramics Pvt. Ltd. under an NCLT-approved resolution for ₹32 crore. This acquisition could not be finalized within the given timeframe. The company also raised funds through a Rights Issue.
What changes now
The audit report has been corrected for procedural clarity. The failed acquisition of Oasis Ceramics means the EMD of ₹55 lakh and consideration of ₹2 crore paid are effectively lost, along with the invoked bank guarantee of ₹3.21 crore. The diversion of Rights Issue funds, though ratified, signals a shift in capital allocation strategy.
Risks to watch
The failed acquisition has put the target entity, Oasis Ceramics, into liquidation proceedings. Auditors noted a lack of a repayment schedule for loans granted by the company, posing risks to asset recoverability. The company is also undergoing corporate restructuring, including the disposal of its stake in Hemonc Pharma and initiating strike-off for its subsidiary, Microcure Biotech.
Peer comparison
Information on specific peers regarding acquisition failures or rights issue fund diversion is not available in the filing. Typically, companies undertaking acquisitions face risks of deal completion. Diversion of funds, even if ratified, can impact investor confidence compared to peers strictly adhering to stated fund utilization.
Context metrics (time-bound)
- Rights Issue Raised: ₹39.97 crore (FY 2025-26)
- Rights Issue Amount Diverted: ₹37.47 crore (FY 2025-26)
- Oasis Ceramics Acquisition Consideration: ₹32 crore (planned)
- Bank Guarantee Invoked (Oasis Ceramics): ₹3.21 crore
- EMD Paid (Oasis Ceramics): ₹55 lakh
- Consideration Paid (Oasis Ceramics): ₹2 crore
- Shareholder Ratification for Fund Diversion: January 22, 2026
What to track next
Investors should closely monitor the company's progress in resolving the liquidation proceedings for Oasis Ceramics and the recovery of any potential remaining assets. Scrutiny of the company's loan portfolio and their repayment schedules will be critical. Furthermore, tracking future capital allocation decisions will be important, especially following the significant rights issue fund diversion.